What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
Biotechnology company Creative Medical Technology Holdings, Inc. seems to be witnessing success in the allogeneic cell therapy market.
In Q4 2022, the company – best known for its regenerative approach to immunotherapy, endocrinology, urology, gynecology and orthopedics – made a significant announcement regarding the successful development of an allogeneic cell line known as AlloStem™. AlloStem™ is a cell line that is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Following FDA approval, the program – referred to as CELZ-201 – is now being utilized in an early type 1 diabetes clinical trial. It will continue to undergo development for the treatment of both type 1 and type 2 Diabetes.
In Q4 2022, the company – best known for its regenerative approach to immunotherapy, endocrinology, urology, gynecology and orthopedics – made a significant announcement regarding the successful development of an allogeneic cell line known as AlloStem™. AlloStem™ is a cell line that is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Following FDA approval, the program – referred to as CELZ-201 – is now being utilized in an early type 1 diabetes clinical trial. It will continue to undergo development for the treatment of both type 1 and type 2 Diabetes.
Transcript
00:00 Created Medical Technology Holdings Inc., NASDAQ ticker CELC, a biotechnology company
00:07 is witnessing success in the allogeneic cell therapy market.
00:11 In Q4 2022, the company, best known for its regenerative approach to immunotherapy, endocrinology,
00:18 urology, gynecology and orthopedics, made a significant announcement regarding the successful
00:23 development of an allogeneic cell line known as Allostem.
00:28 Allostem is a cell line that is derived from human perinatal tissue and includes a master
00:32 cell bank and a drug master file.
00:34 Following FDA approval, the program, referred to as CELZ-201, is now being utilized in an
00:41 early type 1 diabetes clinical trial.
00:44 It will continue to undergo development for the treatment of both type 1 and type 2 diabetes.
00:49 Allogeneic cell therapy can provide patients with a potentially curative treatment option
00:53 where other traditional therapies have been unsuccessful.
00:56 As a relatively new field, research into allogeneic cell therapies is ongoing and the future is
01:01 promising for patients who suffer from these diseases.
01:05 Companies like Argon, Inc., trader on the New York Stock Exchange ticker AGX, are also
01:09 exploring the potential benefits of allogeneic cells.
01:12 With the necessary endorsement from the FDA and an ongoing clinical trial, Created Medical
01:18 Technology's recent development set the stage for innovative treatment options that
01:21 could significantly improve the lives of patients grappling with diabetes and other diseases.
01:26 The global market size for allogeneic cell therapy was $255.6 million in 2022 and it
01:33 is expected to grow at a CAGR of 27.4% from 2023 to 2030, highlighting the value of ongoing
01:40 research.
01:42 As the company remains steadfast in its commitment to medical innovation, its efforts have the
01:46 potential to yield enhanced health outcomes for individuals worldwide.
01:49 (upbeat music)